Enzeshu® (Suvisexumab for Injection) is co-developed by Simcere Zaiming and Pyxis Oncology. Simcere Zaiming completed its preclinical and clinical studies, executed cell line screening and process development using proprietary technology platforms, and manufactured clinical trial supplies. Post-approval, commercial production will be conducted at Simcere Zaiming’s antibody facility in Nanjing Jiangbei New Area.

As a recombinant humanized anti-VEGF monoclonal antibody, Enzeshu® exerts antitumor effects by precisely blocking VEGF-receptor binding to inhibit tumor angiogenesis. It is China’s first anti-angiogenic targeted drug approved for the full platinum-resistant ovarian cancer population, transcending the historically limited therapeutic landscape in this field.